SCHEMBL6565684

SCHEMBL6565684

CC(=O)c1nc2ccccc2cc1OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.63
HTT P42858 4/20 0.63
STAT3 P40763 2/20 0.63
MAPT P10636 4/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
LMNA P02545 2/20 0.51
POLB P06746 1/20 0.51
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAOB P27338 3/20 0.46
BRD4 O60885 1/20 0.46
CA9 Q16790 1/20 0.45
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 1/20 0.43
SRD5A1 P18405 2/20 0.43
SRD5A2 P31213 2/20 0.43
MRGPRX4 Q96LA9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4703021 0.89 SMN1; SMN2 (0.62) SMN1; SMN2HTTSTAT3MAPTL3MBTL1
SCHEMBL8628854 0.86 HTT (0.49) SMN1; SMN2HTTSTAT3MAPTL3MBTL1
SCHEMBL8625960 0.86 HTT (0.49) SMN1; SMN2HTTSTAT3MAPTL3MBTL1
SCHEMBL20067905 0.86 SMN1; SMN2 (0.49) SMN1; SMN2HTTSTAT3MAPTL3MBTL1
SCHEMBL6567304 0.85 HDAC8 (0.56) SMN1; SMN2HTTSTAT3MAPTPOLB
SCHEMBL8628366 0.83 MCL1 (0.47) SMN1; SMN2HTTSTAT3MAPTL3MBTL1
SCHEMBL8629057 0.82 MEN1 (0.52) SMN1; SMN2HTTSTAT3MAOBMEN1
SCHEMBL8630298 0.82 SMN1; SMN2 (0.43) SMN1; SMN2HTTSTAT3MAPTL3MBTL1
SCHEMBL8628372 0.82 MEN1 (0.52) SMN1; SMN2HTTSTAT3MAOBKDM4E
SCHEMBL8632069 0.81 MAOB (0.48) SMN1; SMN2HTTSTAT3MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376154-A1 BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE ZYMEWORKS BC INC. (CA) 2024-11-14 US disclosed
EP-0765871-B1 Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors FIBROGEN INC (US) 2004-03-31 EP disclosed
CN-1120157-C Substituted quinoline-2-carboxamides, process for their preparation and their use as pharmaceuticals, and intermediates thereof FIBER GENE CORP (US) 2003-09-03 CN disclosed
CN-1282737-A Intermediate product used for preparing substituted quinoline-2-formamide MOECHST AG (DE) 2001-02-07 CN disclosed
US-5726305-A Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1998-03-10 US disclosed
US-5719164-A Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1998-02-17 US disclosed
CN-1154365-A Substituted quinoline-2-carboxamides, process for their preparation and their use as pharmaceuticals, and intermediates thereof HOECHST AG (DE) 1997-07-16 CN disclosed
US-5620995-A Substituted heterocyclic carboxyamides, their preparation and their use as pharmaceuticals HOECHST AKTIENGESELLSCHAFT (DE) 1997-04-15 US disclosed
EP-0765871-A1 Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors HOECHST AKTIENGESELLSCHAFT (DE) 1997-04-02 EP disclosed
EP-0661269-B1 Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments HOECHST AG (DE) 1997-03-26 EP disclosed
CN-1126203-A Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals HOECHST AG (DE) 1996-07-10 CN disclosed
EP-0661269-A1 Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments HOECHST AKTIENGESELLSCHAFT (DE) 1995-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376154-A1 BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE PCNA, POLI, VIP SMN1; SMN2 4274/4885HTT 3911/4885STAT3 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.